The Italian External Quality Assessment scheme for fragile x syndrome: the results of a 5-year survey.

The Italian External Quality Assessment scheme for fragile X syndrome started in 2001 as an activity funded by the National Health System and coordinated by the National Institute of Public Health. The aim of this work is to present the data of 5 years (2001--2004 and 2006) of survey. The External Quality Assessment scheme was designed to cover the following points: (a) genotyping and (b) interpretation and reporting of results. Overall, the scheme covered about 65% of all Italian public laboratories. The average reporting of results was 91.6%, with an overall success rate of 76%. The rate of diagnostic errors observed was on average 5%. Inaccuracy in sizing of CGG repeats of normal and premutated alleles was reported. During the survey the proportion of laboratories using a Southern blotting, polymerase chain reaction, and ABI sizing kit in combination rose from 36.8% to 70.6%. The reports from laboratories showed incompleteness and considerable variations in expected outcomes. For this reason, in 2004 a model for written reports was introduced. In conclusion, these data underscore the need to participate in External Quality Assessment schemes as an educational resource to ensure quality in molecular genetic testing.

[1]  E. Eichler,et al.  Length of uninterrupted CGG repeats determines instability in the FMR1 gene , 1994, Nature Genetics.

[2]  P. Hagerman,et al.  The fragile-X premutation: a maturing perspective. , 2004, American journal of human genetics.

[3]  R. Desnick,et al.  Quality assurance in molecular genetic testing laboratories. , 1999, JAMA.

[4]  J. Libeer.  Role of external quality assurance schemes in assessing and improving quality in medical laboratories. , 2001, Clinica chimica acta; international journal of clinical chemistry.

[5]  E. Favaloro,et al.  Type 2B von Willebrand's disease and angiodysplasia. , 1999, Thrombosis and haemostasis.

[6]  M. Hertzberg,et al.  External quality assurance of molecular analysis of haemochromatosis gene mutations , 2006, Journal of Clinical Pathology.

[7]  M. Losekoot,et al.  A European pilot quality assessment scheme for molecular diagnosis of Huntington's disease , 1999, European Journal of Human Genetics.

[8]  W. Brown,et al.  Guidelines for the diagnosis of fragile X syndrome. National Fragile X Foundation. , 1993, Journal of medical genetics.

[9]  W. Brown,et al.  Rapid Fragile X Carrier Screening and Prenatal Diagnosis Using a Nonradioactive PCR Test , 1993 .

[10]  R. Jansen,et al.  EQUAL-qual: a European program for external quality assessment of genomic DNA extraction and PCR amplification. , 2007, Clinical chemistry.

[11]  Dana C Crawford,et al.  FMR1 and the fragile X syndrome: Human genome epidemiology review , 2001, Genetics in Medicine.

[12]  L. Zwaigenbaum,et al.  Paternal transmission of fragile X syndrome , 2004, American journal of medical genetics. Part A.

[13]  C. Yanisch-Perron,et al.  Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vectors. , 1985, Gene.

[14]  R. Bennett,et al.  Genetic Counseling for Fragile X Syndrome: Updated Recommendations of the National Society of Genetic Counselors , 2005, Journal of Genetic Counseling.

[15]  W. Brown,et al.  Expansion of the fragile X CGG repeat in females with premutation or intermediate alleles. , 2003, American journal of human genetics.

[16]  Ben A. Oostra,et al.  Absence of expression of the FMR-1 gene in fragile X syndrome , 1991, Cell.

[17]  E. Dequeker,et al.  Genetic testing and quality control in diagnostic laboratories , 2000, Nature Genetics.

[18]  D. Stoppa-Lyonnet,et al.  External quality assessment for mutation detection in the BRCA1 and BRCA2 genes: EMQN's experience of 3 years. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  Bradley W. Popovich.  Advances for proficiency testing for genetic laboratory science , 2002 .

[20]  S. Antonarakis,et al.  Mutation nomenclature extensions and suggestions to describe complex mutations: A discussion , 2000 .

[21]  W. Grody,et al.  Monitoring standards for molecular genetic testing in the United Kingdom, the Netherlands, and Ireland. , 2006, Genetic testing.

[22]  P. Ahmad-Nejad,et al.  Methodologic European external quality assurance for DNA sequencing: the EQUALseq program. , 2006, Clinical chemistry.

[23]  P. Mannucci,et al.  Relatively Poor Performance of Clinical Laboratories for DNA Analyses in the Detection of Two Thrombophilic Mutations – A Cause for Concern , 2002, Thrombosis and Haemostasis.

[24]  Michael Neumaier,et al.  EQUAL-quant: an international external quality assessment scheme for real-time PCR. , 2006, Clinical chemistry.

[25]  CD O'Connell,et al.  Standardization of PCR amplification for fragile X trinucleotide repeat measurements * , 2002, Clinical genetics.

[26]  Mario Pazzagli,et al.  External quality assurance program for PCR amplification of genomic DNA: an Italian experience. , 2003, Clinical chemistry.

[27]  M. Watson,et al.  Technical Standards and Guidelines for Fragile X: The First of a Series of Disease-Specific Supplements to the Standards and Guidelines for Clinical Genetics Laboratories of the American College of Medical Genetics , 2001, Genetics in medicine : official journal of the American College of Medical Genetics.

[28]  E. Dequeker,et al.  International genetic testing. , 2003 .

[29]  N. Holtzman,et al.  The new genetics: Genetic testing and public policy , 1998, BMJ.

[30]  E. Eichler,et al.  Fine structure of the human FMR1 gene. , 1993, Human molecular genetics.

[31]  J. Sutcliffe,et al.  Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome , 1991, Cell.

[32]  J. Sutcliffe,et al.  Variation of the CGG repeat at the fragile X site results in genetic instability: Resolution of the Sherman paradox , 1991, Cell.

[33]  J. Mandel,et al.  Instability of a 550-base pair DNA segment and abnormal methylation in fragile X syndrome , 1991, Science.

[34]  W. Grody,et al.  Quality control in molecular genetic testing , 2001, Nature Reviews Genetics.

[35]  E. Dequeker,et al.  Towards quality assurance and harmonization of genetic testing services in the European Union , 2004, Nature Biotechnology.

[36]  Shirley A. Miller,et al.  A simple salting out procedure for extracting DNA from human nucleated cells. , 1988, Nucleic acids research.

[37]  E. Eichler,et al.  Robust amplification and ethidium-visible detection of the fragile X syndrome CGG repeat using Pfu polymerase. , 1994, American journal of medical genetics.

[38]  Soma Das,et al.  Technical Standards and Guidelines: Molecular Genetic Testing for Ultra-Rare Disorders , 2005, Genetics in Medicine.

[39]  D. Taruscio,et al.  The Italian External Quality Control Programme for cystic fibrosis molecular diagnosis: 4 years of activity , 2007, Clinical chemistry and laboratory medicine.

[40]  Mark F Bear,et al.  The mGluR theory of fragile X mental retardation , 2004, Trends in Neurosciences.

[41]  É. Khandjian,et al.  The fragile X mental retardation protein is a molecular adaptor between the neurospecific KIF3C kinesin and dendritic RNA granules. , 2007, Human molecular genetics.

[42]  B. Dallapiccola,et al.  Genetic testing in Italy, year 2004 , 2006, European Journal of Human Genetics.

[43]  D. Schlessinger,et al.  Fragile X genotype characterized by an unstable region of DNA , 1991, Science.

[44]  P. Pignatti,et al.  Quality assessment in cytogenetic and molecular genetic testing: the experience of the Italian Project on Standardisation and Quality Assurance , 2004, Clinical chemistry and laboratory medicine.